A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer

NCT06225804 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

164

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: ABSK112

Sponsor

Abbisko Therapeutics Co, Ltd